Product image of Onbrez Breezhaler (Indacaterol) supplied by GNH India

Onbrez Breezhaler

Active Ingredient:
Indacaterol
Origin:
EU

Onbrez Breezhaler (Indacaterol)

Indacaterol, the active ingredient in Onbrez Breezhaler, is a bronchodilator presented as a 150 µg inhalation powder for inhalation use. It provides long‑acting bronchodilation for patients with chronic obstructive pulmonary disease (COPD). GNH India supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Onbrez Breezhaler contains indacaterol, a long‑acting β2‑agonist that relaxes airway smooth muscle in obstructive lung disease.

  • Chronic obstructive pulmonary disease (COPD): improves lung function and reduces symptom burden.
  • Exercise‑induced bronchoconstriction in COPD: maintains airway patency during physical activity.
  • Maintenance therapy for COPD: provides once‑daily bronchodilation to help prevent exacerbations.

How It Works

  • Indacaterol binds selectively to β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing cyclic AMP levels. The rise in cAMP leads to relaxation of bronchial smooth muscle, producing sustained bronchodilation that lasts for at least 24 hours after inhalation.

Side Effects

Adverse reactions reported with indacaterol inhalation are generally mild to moderate.

Common Side Effects

  • Cough: transient irritation of the airway.
  • Throat irritation: mild soreness or dryness.
  • Nasopharyngitis: upper‑respiratory tract infection symptoms.
  • Headache: mild to moderate intensity.
  • Dry mouth: reduced salivation.
  • Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

  • Paradoxical bronchospasm: sudden worsening of airflow obstruction.
  • Cardiovascular events: tachycardia, palpitations, or hypertension.
  • Severe hypersensitivity: rash, angio‑edema, or anaphylaxis.
  • Severe bronchitis or pneumonia: infection requiring medical attention.
  • Acute respiratory failure: rapid decline in breathing function.
  • Chest pain: unexplained thoracic discomfort.

Precautions & Warnings

Patients and healthcare providers should consider several safety points when using indacaterol inhalation therapy.

  • Assess respiratory status: confirm stable COPD before initiating therapy.
  • Review cardiovascular history: monitor for tachycardia or hypertension.
  • Avoid concomitant non‑selective β‑blockers: may reduce bronchodilator effect.
  • Caution in severe hepatic impairment: dose adjustment may be required.
  • Educate on proper inhaler technique: ensures adequate drug delivery.
  • Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Indacaterol may interact with other medicines that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid)

  • Non‑selective β‑blockers: can antagonize bronchodilation and precipitate bronchospasm.
  • Monoamine oxidase inhibitors (MAOIs): may increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance hypokalaemia, requiring electrolyte monitoring.
  • Other long‑acting β2‑agonists: additive bronchodilator effect may increase cardiac risk.
  • Theophylline: potential for increased theophylline plasma concentrations.
  • Anticholinergic bronchodilators: monitor for additive airway effects.
  • Cough suppressants containing codeine: may mask bronchospasm symptoms.

Frequently Asked Questions

Onbrez Breezhaler is an inhaled medication that contains indacaterol, a long‑acting β2‑agonist used as maintenance therapy to improve breathing in adults with chronic obstructive pulmonary disease (COPD). It helps to keep the airways open and reduces symptoms such as shortness of breath and wheezing.

Indacaterol selectively activates β2‑adrenergic receptors on airway smooth‑muscle cells, stimulating adenylate cyclase and raising cyclic AMP levels. The increased cAMP causes smooth‑muscle relaxation, producing sustained bronchodilation that lasts for about 24 hours after each inhalation.

The prescribed dose of Onbrez Breezhaler is determined by a qualified healthcare professional based on the individual’s clinical condition, severity of COPD, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for indacaterol in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Onbrez Breezhaler delivers once‑daily indacaterol, offering 24‑hour bronchodilation, whereas many other long‑acting β2‑agonists require twice‑daily dosing. Its inhaler device provides consistent dose delivery, and clinical studies have shown comparable improvements in lung function to other approved LABA therapies.

Store the Breezhaler device and its capsules at or below 25 °C, protected from moisture, heat and direct sunlight. Keep the product in its original packaging until use to maintain dose integrity.

The patient removes a capsule from the Breezhaler device, inserts it into the inhaler, and inhales forcefully through the mouthpiece as instructed. Proper technique, including a full exhalation before inhalation and a breath‑hold after inhalation, ensures optimal drug delivery.

Serious risks include paradoxical bronchospasm, severe cardiovascular events such as tachycardia or hypertension, and rare hypersensitivity reactions like anaphylaxis. Patients should seek immediate medical attention if they experience sudden worsening of breathing, chest pain, or signs of an allergic reaction.

Onbrez Breezhaler is contraindicated in patients with a known hypersensitivity to indacaterol or any excipients in the formulation, and in individuals who have experienced a severe paradoxical bronchospasm with a β2‑agonist. It should be used with caution in patients with significant cardiac disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Indacaterol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT